Publications

Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma

Yu KH, Ricigliano M, McCarthy B, Chou JF, Capanu M, Cooper B, Bartlett A, Covington C, et al.

Classification of pancreatic Cancer: ready for practical application?

DN Khalil, EM O'Reilly

Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention

MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, M Capanu, ...

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease

E Ter Veer, LB van Rijssen, MG Besselink, RMA Mali, JD Berlin, S Boeck, ...

Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations

ZI Hu, J Shia, ZK Stadler, AM Varghese, M Capanu, E Salo-Mullen, ...

Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma

JJ Harding, G Abu-Zeinah, JF Chou, DH Owen, M Ly, MA Lowery, ...

HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer …

EM O'Reilly, EH Borazanci, KH Yu, AM Varghese, H Estrella, D Kamins, ...

Incidence, management, and implications of visceral thrombosis in pancreatic ductal adenocarcinoma

A Mier-Hicks, M Raj, RK Do, KH Yu, MA Lowery, A Varghese, EM O'Reilly

Metastatic pancreatic cancer: ASCO clinical practice guideline update

DPS Sohal, EB Kennedy, A Khorana, MS Copur, CH Crane, ...

MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.

DY Oh, SE Al-Batran, HC Chung, A Hollebecque, S Iqbal, KP Kim, J Lacy, ...

MORPHEUS: A phase ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with gastric or pancreatic cancer

DY Oh, SE Al-Batran, HC Chung, A Hollebecque, S Iqbal, KP Kim, J Lacy, ...

Nano-liposomal irinotecan and 5-FU/LV (N+ F) for the treatment of advanced PDAC: Memorial Sloan Kettering (MSK) Single Cancer Center Evaluation.

DC Glassman, AM Desai, GY Ku, J Li, JJ Harding, AM Varghese, ...

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

DC Glassman, RL Palmaira, CM Covington, AM Desai, GY Ku, J Li, ...

Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior

Sahin IH, Elias H, Chou JF, Capanu M, O'Reilly EM

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, et al.

Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S).

IH El Dika, M Capanu, JF Chou, JJ Harding, AD Hrabovsky, RKG Do, ...

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma

MA Lowery, DP Kelsen, M Capanu, SC Smith, JW Lee, ZK Stadler, ...

Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.

KH Yu, S Mantha, C Tjan, ES Kaufmann, R Brenner, MA Lowery, GY Ku, ...

Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).

BA Krantz, D Tsui, MA Lowery, M Capanu, KH Yu, DP Kelsen, ...

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance)(C8).

GK Abou-Alfa, Q Shi, JJ Knox, A Kaubisch, J Posey, BR Tan, P Kavan, ...

Preface for special edition pancreas cancer

EM O’Reilly, L Zheng

Prospective analysis of somatic and germline genetic alterations in patients with ampullary carcinomas.

W Wong, EM O'Reilly, AM Varghese, KH Yu, CA Iacobuzio-Donahue, ...

Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms

MA Lowery, W Wong, EJ Jordan, JW Lee, Y Kemel, J Vijai, D Mandelker, ...

Qualitative study of cancer patients’ advance care planning (ACP) values.

R Agarwal, AE Volandes, DR Romano, M Genoff, EM O'Reilly, W Breitbart, ...

Rivaroxaban thromboprophylaxis in high-risk ambulatory cancer patients receiving systemic therapy: results of a randomized clinical trial (CASSINI)

AA Khorana, GA Soff, AK Kakkar, S Vadhan-Raj, H Riess, T Wun, ...

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, et al.

Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.

KA Goodman, N Hall, TS Bekaii-Saab, FS Ou, E Twohy, MO Meyers, ...

Understanding pancreatic diseases using animated pancreas patient: informing patients for better health outcomes with visual formats of learning

S Munigala, TB Gardner, EM O'Reilly, C Fernandez-del Castillo, AH Ko, ...

Variability of pelvic MRI performance in a prospective multicenter rectal cancer trial NCCTG N1048 (Alliance).

MJ Gollub, Q Shi, S Nougaret, P Subramanian, J Zhang, MV Knopp, ...

Visceral thromboses in pancreas adenocarcinoma: systematic review

AM Hicks, A DeRosa, M Raj, R Do, KH Yu, MA Lowery, A Varghese, ...

Visceral Thrombosis in Pancreas Ductal Adenocarcinoma: Incidence, Management and Implications

AM Hicks, M Raj, RK Do, KH Yu, MA Lowery, A Varghese, EM O’Reilly

A novel scoring system to predict survival in patients with advanced pancreatic adenocarcinoma: The Memorial Sloan Kettering Cancer Center (MSKCC) Prognostic Score (MPS).

AC Yang, A Wiesenthal, AS Epstein, J Goldberg, J Meadows, EM O'Reilly, ...

A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma

MA Lowery, KH Yu, DP Kelsen, JJ Harding, JS Bomalaski, DC Glassman, ...

A phase I study of mFOLFOX6 and ADI-PEG-20 in patients (pts) with advanced hepatocellular carcinoma (HCC) and other gastrointestinal (GI) malignancies.

JJ Harding, MA Lowery, K Uhlitskykh, PJ Wan, CR Hamilton, A Barba, ...

A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).

MA Lowery, EM O'Reilly, JJ Harding, KH Yu, A Cercek, E Hollywood, ...

A prospective analysis of germline alterations (GA) in biliary tract cancer (BTC).

MA Lowery, E Jordan, Y Kemel, S Mukherjee, A Cercek, NE Kemeny, ...

A situation where hepatocellular carcinoma (HCC) may be more common in women than men: Clinical and genetic patterns of non risk-factored HCC.

IH El Dika, JJ Harding, M Capanu, MF Berger, D Rebibo, M Rusek, ...

Ablative radiotherapy doses for locally advanced: pancreatic cancer (LAPC)

CH Crane, EM O’Reilly

Acceptability and effects of values-based outpatient advance care planning (ACP) in gastrointestinal (GI) cancers.

AS Epstein, EM O'Reilly, AE Volandes, E Shuk, DR Romano, W Breitbart

Acceptability and effects of values-based outpatient advanced care planning (ACP) in gastrointestinal (GI) cancers.

AS Epstein, EM O'Reilly, AE Volandes, Y Li, E Shuk, W Breitbart

Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of …

CS Fuchs, D Niedzwiecki, HJ Mamon, JE Tepper, X Ye, RS Swanson, ...

Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline …

MHG Katz, FS Ou, JM Herman, SA Ahmad, B Wolpin, R Marsh, S Behr, ...

Alliance for clinical trials in oncology trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable …

MHG Katz, FS Ou, J Herman, SA Ahmad, BM Wolpin, RW Marsh, Q Shi, ...

An audit of a bariatric sleep service

E O'Reilly, C O'Boyle, L Doherty

An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses

N Vasan, MI Braghiroli, AN Shoushtari, RKG Do, M Edelweiss, ...

Biodistribution and radiation rose estimates for 89Zr-DFO-HuMab-5B1 (MVT-2163) in CA19-9 positive cancer: first-in-man results

J O'Donoghue, C Lohrmann, E O'Reilly, K Yu, M Lowery, S Lyashchenko, ...

Brain metastases (BM) in pancreatic ductal adenocarcinoma (PDAC): Clinical and molecular characteristics.

E Jordan, TJ Kaley, M Capanu, H Estrella, SD Leach, O Basturk, ...

Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy

EJ Jordan, O Basturk, J Shia, DS Klimstra, W Alago, MI D’Angelica, ...

Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection

F Huguet, C Hajj, CB Winston, W Shi, Z Zhang, AJ Wu, EM O’Reilly, ...

Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations.

ZI Hu, AM Varghese, J Shia, A Zervoudakis, MA Lowery, KH Yu, ...